A Phase 3 interventional study of GZR18 and Semaglutide(Wegovy® ) in Obesity/Overweight in Adult, sponsored by Gan & Lee Pharmaceuticals.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-25.
Sponsored by Gan & Lee Pharmaceuticals. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing bofanglutide in Obesity — 3 open to participants now, 3 under way, 3 of them phase 3. bofanglutide · Obesity.
Among the 15 studies testing bofanglutide in Obesity, this one is the 2nd largest by planned enrollment, is one of 6 that started in 2025, is one of 5 in phase 3, and was the 11th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →3 of the 15 studies testing bofanglutide in Obesity are open now, in 2 countries. Recruiting first, the newest first:
Gan & Lee Pharmaceuticals. · Sites in China
Ages 18+
Carnot Laboratories · Sites in Mexico
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 5
First in 2021; this study’s year is marked. 6 started in 2025.
This study's planned enrollment of 420 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 140 across the 15 interventional studies. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 3 most frequent:
This study is registered under Gan & Lee Pharmaceuticals., one of the names counted as Gan & Lee Pharmaceuticals. Under that name alone:
Gan & Lee Pharmaceuticals. is the lead sponsor of 29 studies on the registry; 14 are open to participants now.
15 studies in Obesity by Gan & Lee Pharmaceuticals: 3 open now, 3 under way, 2 of them phase 3. Of 12 finished, 0 (0%) have results posted.
Among the 15 studies in Obesity by Gan & Lee Pharmaceuticals, this one is the 2nd largest by planned enrollment, is one of 6 that started in 2025, is one of 4 in phase 3, and was the 11th registered.
Gan & Lee Pharmaceuticals’s Obesity studies by the year they started, since 2021.
2 of the studies testing bofanglutide in Obesity that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07150975Phase 3Gan & Lee Pharmaceuticals.Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects | 2027-06-30 |
| NCT07493057Phase 3Gan & Lee Pharmaceuticals.Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy | 2027-11-14 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies testing bofanglutide in Obesity, from their registry updates:
Among Gan & Lee Pharmaceuticals’s 15 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study is a multicenter, randomized, open-label, parallel-group phase III clinical trial comparing the efficacy and safety of GZR18 Injection and semaglutide (Wegovy®) in adult obese or overweight subjects, aiming to evaluate the efficacy and safety of GZR18 Injection in this population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For subjects not diagnosed with type 2 diabetes at screening, the following criteria must be met:
At screening and Visit 2 (before randomization), the subject must be either obese ( ≥ 28 kg/m²) or overweight (24 kg/m² ≤ BMI \< 28 kg/m²), and concurrently present with at least one of the following conditions:
Comorbidity of one or more of the following: hyperglycemia (see Appendix 1 for definition), hypertension, dyslipidemia (see Appendix 2 for definition), or fatty liver; ②Weight-bearing joint pain;
For subjects with type 2 diabetes at screening, the following criteria must be met simultaneously:
Body mass index (BMI) ≥ 24 kg/m² at both screening and Visit 2 (before randomization); A confirmed diagnosis of type 2 diabetes for at least 90 days at screening, in accordance with the World Health Organization (WHO) 1999 diabetes diagnostic criteria and the 2011 supplementary diagnostic criteria (-based diagnosis is recommended); Within 90 days prior to screening: ① Management through diet and exercise alone, with no use of any antidiabetic medications; or ② Treatment of type 2 diabetes with a stable dose of metformin monotherapy, where the metformin dose is ≥ 1500 mg/day or the maximum tolerated dose (\< 1500 mg/day but ≥ 1000 mg/day); or ③ Treatment of type 2 diabetes with a stable dose of metformin (≥ 1500 mg/day or the maximum tolerated dose (\< 1500 mg/day but ≥ 1000 mg/day)) combined with a stable dose of sodium-glucose cotransporter 2 inhibitor (SGLT2i); Glycated hemoglobin (HbA1c) measured by the central laboratory at screening is 7.0-10.5% (inclusive of both endpoints); Fasting plasma glucose measured by the central laboratory at screening is \< 15 mmol/L.
The subject must be able to understand the procedures and methods of this study, be willing and able to maintain a regular diet and exercise lifestyle during the study period, be willing and able to receive subcutaneous injection of the product, and voluntarily sign the informed consent form.
-
Exclusion Criteria:
For subjects without type 2 diabetes at screening, the following situations are excluded:
Fasting plasma glucose ≥ 7.0 mmol/L or (HbA1c) ≥ 6.5% as measured by the central laboratory at screening.
Diagnosis of any type of diabetes (excluding gestational diabetes) prior to screening.
For subjects with type 2 diabetes at screening, the following situations are excluded:
Use of glucagon-like peptide-1 receptor (GLP-1R) agonists or drugs with a GLP-1R agonist mechanism of action (e.g., GLP-1R/glucagon receptor (GCGR) agonists, glucose-dependent insulinotropic polypeptide receptor (GIPR)/GLP-1R agonists, or GIPR/GLP-1R/GCGR agonists, etc.) within 180 days prior to screening; or a history of poor blood glucose control efficacy or intolerance to the above-mentioned drugs (as assessed by the investigator).
A history of diabetic ketoacidosis, lactic acidosis, or hyperosmolar hyperglycemic state within 180 days prior to screening.
Presence of severe chronic diabetic complications at screening (e.g., proliferative retinopathy or macular edema, painful diabetic neuropathy, intermittent claudication, or diabetic foot).
The investigator deems that the subject has any other factors that may affect the evaluation of efficacy or safety in this study, making them unsuitable for participation.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: GZR18
Drug: GZR18
Drug: Semaglutide(Wegovy® )
Administered SC
Administered SC
Percentage change in body weight from baseline after 52 weeks (W) of treatment.
Time frame: From Week 0 to Week 52
Efficacy Outcome Measure :Percentage of subjects with body weight reduction ≥ 5% from baseline
Time frame: From Week 0 to Week 52
Efficacy Outcome Measure :Percentage of subjects with body weight reduction ≥ 10% from baseline
Time frame: From Week 0 to Week 52
Efficacy Outcome Measure :Percentage of subjects with body weight reduction ≥ 15% from baseline
Time frame: From Week 0 to Week 52
Efficacy Outcome Measure :Percentage of subjects with body weight reduction ≥ 20% from baseline
Time frame: From Week 0 to Week 52
Efficacy Outcome Measure :Percentage of subjects with body weight reduction ≥ 25% from baseline
Time frame: From Week 0 to Week 52
Efficacy Outcome Measure :Changes in body weight from baseline
Time frame: From Week 0 to Week 52
Efficacy Outcome Measure :Changes in body mass index (BMI) from baseline
Time frame: From Week 0 to Week 52
Efficacy Outcome Measure :Changes in waist circumference from baseline
Time frame: From Week 0 to Week 52
Efficacy Outcome Measure :Changes from baseline in glycated hemoglobin (HbA1c)
Time frame: From Week 0 to Week 52
Efficacy Outcome Measure :Changes from baseline in fasting plasma glucose
Time frame: From Week 0 to Week 52
Efficacy Outcome Measure :Changes from baseline in fasting insulin
Time frame: From Week 0 to Week 52
Efficacy Outcome Measure :Changes insystolic blood pressure from baseline
Time frame: From Week 0 to Week 52
Efficacy Outcome Measure :Changes in diastolic blood pressure from baseline
Time frame: From Week 0 to Week 52
Efficacy Outcome Measure :Changes from baseline in total cholesterol (TC)
Time frame: From Week 0 to Week 52
Efficacy Outcome Measure :Changes from baseline in low-density lipoprotein cholesterol (LDL-C)
Time frame: From Week 0 to Week 52
Efficacy Outcome Measure :Changes from baseline in high-density lipoprotein cholesterol (HDL-C)
Time frame: From Week 0 to Week 52
Efficacy Outcome Measure :Changes from baseline in triglycerides (TG)
Time frame: From Week 0 to Week 52
Started Sep 2025 (actual). Primary completion is estimated for Jun 2027, 21 months after the start.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 21 months is close to that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bofanglutide